Windlas Biotech (WINDLAS) — Board Meeting

📢 Key Event
Board approved Q1 FY26 results and FY26 dividend

🔄 What Changed
Revenue increased to ₹2,532.12 crores; dividend declared at ₹6.30 per share

💡 Investor Takeaway
The dividend approval and share buyback signal management's confidence in cash flow, but dissolution of the US subsidiary removes a reporting segment without immediate financial impact.

Windlas Biotech's board approved unaudited Q1 FY26 results showing revenue of ₹2,532.12 crores, up from ₹2,428.97 crores in Q4 FY26, with profit after tax at ₹176.53 crores. The board also approved a Rs. 6.30 per share dividend for FY26 and a Rs. 470 million share buyback. The company dissolved its US subsidiary Windlas Inc. effective March 31, 2026, ending consolidated reporting. The limited review by auditors confirmed no material misstatements in the financials.

📄 View Original Announcement (PDF)

📊 Stock Analysis — WINDLAS ✨ Ask AI About This

About Windlas Biotech Limited (WINDLAS)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,645.02 Cr P/E: 26.4

View full WINDLAS stock details →

📡 Get AI alerts when WINDLAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track WINDLAS — Free

💡 Ask AI about this filing

"What is the expected EPS impact of the share buyback?" "How will the US subsidiary dissolution affect future growth plans?" "What is the company's plan for capital allocation post-dividend?"

Ask AI Free →

📊 More WINDLAS filings

See all WINDLAS filings →

🔥 Also filed on 10 August 2026

TIMKEN Timken India Limited Financial Results AMJLAND Amj Land Holdings Limited Annual Report DOMS DOMS Industries Limited Corporate Action HGS Hinduja Global Solutions Limited Financial Results SUNDRMFAST Sundram Fasteners Limited Financial Results KANSAINER Kansai Nerolac Paints Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when WINDLAS files new disclosures

Track WINDLAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.